SUPPLEMENTARY TABLE 1. Influence of VRC treatment on *Cyp* mRNA levels in livers of wild-type, *Pxr*-null, and *Car*-null mice.

	Wild-type			*Pxr*-null			*Car*-null		
	Vehicle	VRC	Fold	Vehicle	VRC	Fold	Vehicle	VRC	Fold
Cyp1a2	1.0 ± 0.1	1.3 ± 0.3	1.3	0.8 ± 0.1	1.3 ± 0.4*	1.6	0.8 ± 0.1	1.2 ± 0.2**	1.5
Cyp2b10	1.0 ± 0.8	61.4 ± 15.0***	61.4	1.2 ± 0.9	75.6 ± 9.8***	61.9	0.1 ± 0.1	1.5 ± 0.5**	16.5
Cyp2c29	1.0 ± 0.1	4.5 ± 0.9***	4.5	3.3 ± 0.6	7.6 ± 1.2***	2.3	0.1 ± 0.0	2.5 ± 0.7***	28.4
Cyp2c37	1.0 ± 0.2	2.4 ± 0.7**	2.4	0.8 ± 0.1	3.3 ± 0.4***	4.0	0.3 ± 0.1	0.6 ± 0.1***	2.2
Cyp2c55	1.0 ± 0.1	29.4 ± 2.5***	29.4	6.7 ± 0.6	36.9 ± 2.6***	5.5	0.4 ± 0.2	7.8 ± 2.9**	17.7
Cyp3a11	1.0 ± 0.2	10.6 ± 5.3*	10.6	1.1 ± 0.2	10.1 ± 5.2*	9.0	1.1 ± 0.3	9.8 ± 5.4*	9.3

VRC was orally administered to wild-type, *Pxr*-null, and *Car*-null mice at 30 mg/kg for 7 days. Hepatic *Cyp* mRNA levels were determined by real-time PCR, and normalized with those of *β-actin*. Relative mRNA levels are shown as the mean ± SD (n=4). Fold induction (Fold) by VRC treatment are calculated by dividing mRNA levels in VRC-treated mice with those in vehicle-treated mice. *: $P < 0.05$, **: $P < 0.01$, ***: $P < 0.001$, compared to strain-matched and vehicle-treated mice.

SUPPLEMENTARY TABLE 2. Influence of VRC treatment on *Cyp* mRNA levels in livers of wild-type and *Pxr/Car*-null mice.

	Wild-type			*Pxr/Car*-null		
	Vehicle	VRC	Fold	Vehicle	VRC	Fold
Cyp1a2	1.0 ± 0.1	1.9 ± 0.2***	1.9	1.3 ± 0.2	1.5 ± 0.2	1.1
Cyp2b10	1.0 ± 0.7	204.4 ± 25.2***	204.4	0.9 ± 1.1	0.5 ± 0.5	0.6
Cyp2c29	1.0 ± 0.2	3.8 ± 0.4***	3.8	2.7 ± 0.6	3.0 ± 1.2	1.1
Cyp2c37	1.0 ± 0.1	3.3 ± 0.5***	3.3	0.8 ± 0.2	1.1 ± 0.8	1.4
Cyp2c55	1.0 ± 0.4	13.3 ± 2.2***	13.3	6.3 ± 0.8	4.9 ± 0.3*	0.8
Cyp3a11	1.0 ± 0.2	6.3 ± 0.9***	6.3	1.4 ± 0.2	1.7 ± 0.6	1.2

VRC was orally administered to wild-type and *Pxr/Car*-null mice at 30 mg/kg for 7 days. Hepatic *Cyp* mRNA levels were determined by real-time PCR, and normalized with those of *β-actin*. Relative mRNA levels are shown as mean ± SD (n=4). Fold induction (Fold) by VRC treatment are calculated by dividing mRNA levels in VRC-treated mice with those in vehicle-treated mice. *: $P < 0.05$, ***: $P < 0.001$, compared to strain-matched and vehicle-treated mice.

SUPPLEMENTARY TABLE 3. Influence of VRC treatment on *Fmo* mRNA levels in livers of wild-type and *Pxr/Car*-null mice

	Wild-type			*Pxr/Car*-null		
	Vehicle	VRC	Fold	Vehicle	VRC	Fold
Fmo1	1.0 ± 0.1	1.3 ± 0.1**	1.3	1.8 ± 0.6	1.7 ± 0.6	0.9
Fmo2	1.0 ± 0.3	1.3 ± 0.4	1.3	2.2 ± 1.4	2.8 ± 2.7	1.3
Fmo3	1.0 ± 1.7	0.7 ± 0.6	0.7	1.0 ± 1.3	0.2 ± 0.2	0.2
Fmo5	1.0 ± 0.1	1.6 ± 0.2***	1.6	1.4 ± 0.2	1.6 ± 0.3	1.2

VRC was orally administered to wild-type and *Pxr/Car*-null mice at 30 mg/kg for 7 days. Hepatic *Fmo* mRNA levels were determined by real-time PCR, and normalized with those of *β-actin*. Relative mRNA levels are shown as mean ± SD (n=4). Fold induction (Fold) by VRC treatment are calculated by dividing mRNA levels in VRC-treated mice with those in vehicle-treated mice. **: $P < 0.01$, ***: $P < 0.001$, compared to strain-matched and vehicle-treated mice.